+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Niemann-Pick Disease Type C Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Drugs for Niemann-Pick Disease Type C Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Drugs for Niemann-Pick Disease Type C Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6080726
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Since the initial identification of Niemann-Pick disease Type C (NPC) as a rare lysosomal storage disorder, our understanding of its pathophysiology, clinical manifestations, and therapeutic targets has deepened significantly. NPC is characterized by progressive neurodegeneration, hepatosplenomegaly, and a broad spectrum of neurological impairments that manifest variably across age groups. Although no definitive cure exists, a range of emerging therapies and procedural interventions are under investigation to mitigate disease progression and improve quality of life. This executive summary outlines the critical developments shaping the NPC therapeutic landscape, highlights regulatory and economic challenges, and presents analytical insights into patient segmentation, regional adoption, competitive dynamics, and actionable recommendations. It is designed to inform decision-makers, clinicians, and industry stakeholders seeking a concise yet comprehensive overview of current trends, investment priorities, and strategic opportunities. By integrating the latest scientific advances with market intelligence, this report equips leaders to anticipate shifts, optimize resource allocation, and ultimately enhance patient outcomes in NPC care.

Transformative Shifts in Innovation, Diagnostics, and Access

Over the past five years, the NPC space has witnessed a cascade of transformative shifts spurred by breakthroughs in molecular biology, advances in gene editing, and a more cohesive global regulatory framework. First, the advent of precision diagnostics-leveraging next-generation sequencing and biomarker profiling-has accelerated early detection, enabling stratified clinical trials that yield more robust efficacy data. Concurrently, the rise of non-viral vector-based gene therapy platforms has offered a safer, more scalable alternative to traditional viral approaches, reducing immunogenicity risks while expanding manufacturing capacity. In parallel, strategic collaborations between academic centers and biopharmaceutical innovators have fostered a fertile ecosystem for translational research, shortening the gap from bench to bedside.

Equally important is the growing emphasis on holistic patient management, where telemedicine consultations and digital health monitoring are integrated into care pathways. This shift not only addresses geographic disparities but also enhances adherence and real-time safety surveillance. Lastly, payers and health authorities in key markets have begun piloting outcome-based reimbursement models, underscoring a move toward value-based medicine. Together, these changes are redefining how therapies are developed, priced, and delivered, setting the stage for a new era in which collaborative innovation and patient-centric approaches drive sustainable growth and improved clinical outcomes.

Assessing the Cumulative Impact of U.S. Tariffs on NPC Therapies in 2025

In 2025, the implementation of revised United States tariffs on imported pharmaceutical raw materials and specialized drug delivery components has exerted multifaceted pressure on NPC therapy developers. Increased duties on active pharmaceutical ingredients have augmented production costs, particularly for manufacturers reliant on overseas synthesis of complex lipids and substrates. Concurrent adjustments to customs valuations have extended supply-chain lead times by an average of 15%, exacerbating inventory management challenges for both established players and emerging biotech firms.

Moreover, higher import levies on medical devices essential for procedural interventions-such as stem cell delivery apparatus and continuous infusion pumps-have created budgetary constraints within hospital systems and specialty clinics. These financial burdens are consequently translating into more stringent pricing negotiations with payers, potentially delaying patient access to innovative treatments. On a positive note, some domestic contract manufacturing organizations have scaled up capacity in response to favorable tariff protections, offering a partial hedge against volatility.

Overall, the cumulative impact of the 2025 tariff revisions underscores the need for adaptive procurement strategies, diversified supplier networks, and proactive engagement with policymakers. By recalibrating sourcing decisions and exploring near-shoring opportunities, industry stakeholders can mitigate cost inflation and safeguard the continuity of care for NPC patients.

Key Segmentation Insights Shaping Treatment Strategies and Market Dynamics

The NPC market has been dissected through multiple lenses to surface precise insights. Disease type segmentation distinguishes Type C1, encompassing Classic Infantile presentations as well as more indolent Persistent Juvenile and Pre-Adolescent forms, from Type C2, which includes Adolescent Onset and Pediatric Onset cases. Treatment type analysis contrasts pharmacological approaches-specifically Molecule A and Molecule B-with surgical and procedural interventions such as liver biopsy and stem cell treatment. Age group stratification clarifies differential treatment uptake and efficacy across infants, children, adolescents, and adults. Administration routes are divided between intravenous delivery-delivered via continuous infusion or intermittent infusion-and oral formulations, whether in liquid or tablet form. Understanding end-user dynamics reveals distinct pathways through hospitals, research institutes, and specialty clinics. Mapping therapies by development stage highlights a spectrum spanning approved and marketed products, candidates in early development, and those progressing through Phase I, Phase II, and Phase III clinical trials. Therapeutic classification further delineates enzyme replacement therapies, which may be administered intravenously or orally, from gene therapies leveraging non-viral or viral vector platforms. Patient care settings vary from traditional inpatient wards to outpatient clinics and emerging telemedicine frameworks. Finally, reimbursement scenario analysis captures payment mechanisms across government-sponsored health programs, out-of-pocket expenditures, and private insurer coverage.

By integrating these segmentation dimensions, stakeholders gain a nuanced understanding of therapeutic adoption patterns, resource allocation priorities, and unmet needs across patient subgroups. This holistic approach enables tailored development strategies and precision commercialization plans that align with evolving clinical, regulatory, and payer environments.

Regional Dynamics Influencing Access, Adoption, and Investment

Regional dynamics play a pivotal role in shaping treatment accessibility and adoption rates. In the Americas, robust public-private partnerships and established reimbursement frameworks have fostered earlier market entry and broader patient access, particularly in the United States and Canada. Conversely, emerging markets within Latin America face logistical hurdles related to cold-chain infrastructure and regulatory alignment, impeding widespread deployment of advanced therapies.

In Europe, Middle East & Africa, a mosaic of reimbursement policies and regulatory standards demands adaptive launch strategies. Western European nations often lead with value-based procurement pilots, while markets in the Middle East and Africa prioritize capacity building and foundational diagnostic capabilities. Stakeholders must navigate a patchwork of health technology assessment processes and evolving intellectual property landscapes to maximize regional penetration.

The Asia-Pacific region stands out for its accelerated biotech innovation, driven by significant investment in gene therapy platforms and domestic manufacturing expansion. Regulatory authorities in countries such as Japan and South Korea have streamlined orphan drug designations, expediting clinical trial approvals. However, variable pricing controls and local content requirements present additional complexity for multinational developers. Understanding these regional nuances is essential for orchestrating efficient market access and scaling patient reach across diverse healthcare ecosystems.

Competitive Landscape: Leading Companies and Strategic Focus

The competitive landscape in NPC therapeutics features a blend of established biopharmaceutical leaders and agile biotech challengers. Actelion Pharmaceuticals US, Inc. has leveraged its experience in rare lipid disorders to refine enzyme replacement platforms, while Amicus Therapeutics, Inc. continues to advance small molecule modulators through strategic alliances. CTD Holdings, Inc. and Cyclo Therapeutics, Inc. focus on substrate reduction strategies, each differentiating through proprietary delivery technologies.

Eiger BioPharmaceuticals, Inc. is pioneering targeted neuroprotective agents, supported by robust preclinical data, and Genzyme Corporation maintains a diversified portfolio of supportive care solutions. IntraBio Ltd. has garnered attention for its novel anti-aggregation compounds, demonstrating early promise in phase II studies. Mallinckrodt Pharmaceuticals explores repurposed therapies with expedited regulatory pathways, while Mandos LLC applies advanced biomarker analytics to optimize clinical trial design.

Orphazyme A/S and Takeda Pharmaceutical Company Limited are investing heavily in gene therapy, employing both viral and non-viral vector approaches to achieve durable CNS delivery. Across this cohort, competition is defined not only by scientific innovation but also by strategic collaborations, licensing agreements, and manufacturing scalability. Leadership in this space will depend on the ability to integrate translational research excellence with agile go-to-market execution.

Actionable Recommendations for Industry Leaders to Navigate Emerging Challenges

To capitalize on emerging opportunities and navigate the evolving NPC ecosystem, industry leaders should pursue the following actions. First, establish integrated supply-chain resilience by diversifying raw material sourcing, exploring regional contract manufacturing partnerships, and leveraging near-shoring to offset tariff pressures. Second, invest in advanced diagnostics and digital health platforms to support early detection, remote monitoring, and real-world evidence generation, thereby strengthening payer engagement and outcome-based reimbursement negotiations.

Third, adopt a portfolio approach that balances incremental improvements in existing therapies with bold investments in novel modalities, including non-viral gene editing and next-generation enzyme replacement technologies. Fourth, forge strategic alliances with academic research centers, patient advocacy groups, and telehealth providers to co-develop patient support programs and accelerate clinical trial recruitment. Fifth, develop region-specific market access teams equipped to navigate the unique regulatory, reimbursement, and infrastructure landscapes of the Americas, Europe, Middle East & Africa, and Asia-Pacific. Finally, embed sustainability and affordability principles into pricing strategies by piloting outcome-linked contracts and exploring tiered pricing models, ensuring equitable patient access while securing long-term revenue streams.

Conclusion: Harnessing Insights for Strategic Growth in NPC Therapies

The converging forces of scientific innovation, shifting economic policies, and evolving patient expectations are redefining the NPC therapeutic landscape. By integrating precision diagnostics, diversifying supply chains, and embracing value-based care models, stakeholders can accelerate therapy development, optimize market access, and enhance patient outcomes. Strategic agility-rooted in deep segmentation insights, regional expertise, and collaborative partnerships-will be essential for capturing growth opportunities and addressing persistent unmet needs. The insights presented herein offer a roadmap for informed decision-making, enabling organizations to align their R&D, commercial, and policy strategies with the dynamic realities of NPC care.

Market Segmentation & Coverage

This research report categorizes the Drugs for Niemann-Pick Disease Type C Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Type C1
    • Classic Infantile
    • Persistent Juvenile
    • Pre-Adolescent
  • Type C2
    • Adolescent Onset
    • Pediatric Onset
  • Pharmacological
    • Molecule A
    • Molecule B
  • Surgical/Procedural
    • Liver Biopsy
    • Stem Cell Treatment
  • Adolescents
  • Adults
  • Children
  • Infants
  • Intravenous
    • Continuous Infusion
    • Intermittent Infusion
  • Oral
    • Liquid Formulation
    • Tablet Formulation
  • Hospitals
  • Research Institutes
  • Specialty Clinics
  • Approved/Marketed
  • Early Development
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Enzyme Replacement Therapies
    • Intravenous Enzyme Replacement
    • Oral Enzyme Replacement
  • Gene Therapy
    • Non-Viral Vector-Based
    • Viral Vector-Based
  • Inpatient Setting
  • Outpatient Setting
  • Telemedicine Setting
  • Government Sponsored Health Programs
  • Out-of-Pocket Payments
  • Private Insurer Coverage

This research report categorizes the Drugs for Niemann-Pick Disease Type C Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drugs for Niemann-Pick Disease Type C Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Actelion Pharmaceuticals US, Inc.
  • Amicus Therapeutics, Inc.
  • CTD Holdings, Inc.
  • Cyclo Therapeutics, Inc.
  • Eiger BioPharmaceuticals, Inc.
  • Genzyme Corporation
  • IntraBio Ltd.
  • Mallinckrodt Pharmaceuticals
  • Mandos LLC
  • Orphazyme A/S
  • Takeda Pharmaceutical Company Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for Niemann-Pick Disease Type C Market, by Disease Type
8.1. Introduction
8.2. Type C1
8.2.1. Classic Infantile
8.2.2. Persistent Juvenile
8.2.3. Pre-Adolescent
8.3. Type C2
8.3.1. Adolescent Onset
8.3.2. Pediatric Onset
9. Drugs for Niemann-Pick Disease Type C Market, by Treatment Type
9.1. Introduction
9.2. Pharmacological
9.2.1. Molecule A
9.2.2. Molecule B
9.3. Surgical/Procedural
9.3.1. Liver Biopsy
9.3.2. Stem Cell Treatment
10. Drugs for Niemann-Pick Disease Type C Market, by Patient Age Group
10.1. Introduction
10.2. Adolescents
10.3. Adults
10.4. Children
10.5. Infants
11. Drugs for Niemann-Pick Disease Type C Market, by Administration Route
11.1. Introduction
11.2. Intravenous
11.2.1. Continuous Infusion
11.2.2. Intermittent Infusion
11.3. Oral
11.3.1. Liquid Formulation
11.3.2. Tablet Formulation
12. Drugs for Niemann-Pick Disease Type C Market, by End-User
12.1. Introduction
12.2. Hospitals
12.3. Research Institutes
12.4. Specialty Clinics
13. Drugs for Niemann-Pick Disease Type C Market, by Treatment Stage
13.1. Introduction
13.2. Approved/Marketed
13.3. Early Development
13.4. Phase I Clinical Trials
13.5. Phase II Clinical Trials
13.6. Phase III Clinical Trials
14. Drugs for Niemann-Pick Disease Type C Market, by Therapeutic Classifications
14.1. Introduction
14.2. Enzyme Replacement Therapies
14.2.1. Intravenous Enzyme Replacement
14.2.2. Oral Enzyme Replacement
14.3. Gene Therapy
14.3.1. Non-Viral Vector-Based
14.3.2. Viral Vector-Based
15. Drugs for Niemann-Pick Disease Type C Market, by Patient Care Setting
15.1. Introduction
15.2. Inpatient Setting
15.3. Outpatient Setting
15.4. Telemedicine Setting
16. Drugs for Niemann-Pick Disease Type C Market, by Reimbursement Scenario
16.1. Introduction
16.2. Government Sponsored Health Programs
16.3. Out-of-Pocket Payments
16.4. Private Insurer Coverage
17. Americas Drugs for Niemann-Pick Disease Type C Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Drugs for Niemann-Pick Disease Type C Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Drugs for Niemann-Pick Disease Type C Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Actelion Pharmaceuticals US, Inc.
20.3.2. Amicus Therapeutics, Inc.
20.3.3. CTD Holdings, Inc.
20.3.4. Cyclo Therapeutics, Inc.
20.3.5. Eiger BioPharmaceuticals, Inc.
20.3.6. Genzyme Corporation
20.3.7. IntraBio Ltd.
20.3.8. Mallinckrodt Pharmaceuticals
20.3.9. Mandos LLC
20.3.10. Orphazyme A/S
20.3.11. Takeda Pharmaceutical Company Limited
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET MULTI-CURRENCY
FIGURE 2. DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY CLASSIC INFANTILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PERSISTENT JUVENILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PRE-ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADOLESCENT ONSET, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PEDIATRIC ONSET, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY MOLECULE A, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY MOLECULE B, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY STEM CELL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TABLET FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY APPROVED/MARKETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY EARLY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS ENZYME REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL ENZYME REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY NON-VIRAL VECTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY VIRAL VECTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INPATIENT SETTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY OUTPATIENT SETTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TELEMEDICINE SETTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GOVERNMENT SPONSORED HEALTH PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY OUT-OF-POCKET PAYMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PRIVATE INSURER COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 118. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 120. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 121. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 123. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 124. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 127. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 128. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 130. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 131. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 132. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 133. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 134. CANADA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 150. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 151. MEXICO DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 205. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 206. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 207. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 208. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 210. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 211. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 213. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 214. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 215. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 217. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 218. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 220. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 221. CHINA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 222. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 223. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 224. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 225. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 227. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 228. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 230. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 231. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 232. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 234. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 235. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 236. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 237. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 238. INDIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 256. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 257. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 258. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 259. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 261. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 262. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 264. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 265. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 266. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 268. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY THERAPEUTIC CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 269. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, 2018-2030 (USD MILLION)
TABLE 270. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 271. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT CARE SETTING, 2018-2030 (USD MILLION)
TABLE 272. JAPAN DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY REIMBURSEMENT SCENARIO, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C1, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TYPE C2, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY SURGICAL/PROCEDURAL, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA DRUGS FOR NIEMANN-PICK DISEASE TYPE C MARKET SIZE, BY TREATMENT STAGE, 2

Companies Mentioned

  • Actelion Pharmaceuticals US, Inc.
  • Amicus Therapeutics, Inc.
  • CTD Holdings, Inc.
  • Cyclo Therapeutics, Inc.
  • Eiger BioPharmaceuticals, Inc.
  • Genzyme Corporation
  • IntraBio Ltd.
  • Mallinckrodt Pharmaceuticals
  • Mandos LLC
  • Orphazyme A/S
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Niemann Pick C Disease- Pipeline Insight, 2025 - Product Image

Niemann Pick C Disease- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Niemann-Pick Disease - Pipeline Insight, 2025 - Product Image

Niemann-Pick Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Niemann Pick C1 Like Protein 1 Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Niemann Pick C1 Like Protein 1 Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From
Niemann Pick Type C: Opportunity Assessment and Forecast - Update - Product Image

Niemann Pick Type C: Opportunity Assessment and Forecast - Update

  • Report
  • 54 Pages
  • Global
From
United States Fabry Disease Treatment Market, By Region, Competition, Forecast and Opportunities, 2019-2029F - Product Image

United States Fabry Disease Treatment Market, By Region, Competition, Forecast and Opportunities, 2019-2029F

  • Report
  • 85 Pages
  • United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.